drugset / Trial / NCT07189455

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

NCT07189455

Phase 3 Recruiting 420 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Timeline

Start
2025-12-12
Primary completion
2028-10
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Topotecan Small molecule
Subject ZG006 Unknown 10 mg Intravenous